Academic Editor: Julio Núñez Villota
Initially intended as an adjunct treatment for type 2 diabetes mellitus (T2DM), SGLT2-inhibitors (SGLT2i) have transformed into an unexpected pillar of the heart failure (HF) regimen. The past several years have witnessed a meteoric rise of this drug class, starting with the serendipitous results of trials assessing the safety of the glucose-lowering therapy in a broad range of cardiovascular patients and culminating with the demonstration of a reduction in hospitalizations for heart failure and cardiovascular mortality in dedicated heart failure populations. The heart failure benefits of SGLT2i are independent of a patient’s glycemic status, but the salient mechanisms of cardioprotection remain a subject of robust debate and ongoing research. Cardiologists as well as physicians of other disciplines should become familiar with the main indications, benefits, and clinical consideration of implementation. In this review, we will discuss the advance of SGLT2i in heart failure, ranging from the results of large randomized clinical trials to potential mechanisms of action.
In 2013, canagliflozin became the first SGLT-2 inhibitor (SGLT2i) approved in the United States for type 2 diabetes mellitus (T2DM). Since then, several of these compounds have been developed and approved for clinical use. Currently, there are four SGLT2i available in the United States and Europe, which include, canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.
In the 2000’s, concerns began to develop around the cardiovascular safety of glucose-lowering therapies . This culminated in 2007 when a signal for increased myocardial infarction with the thiazolidinedione rosiglitazone was identified , which prompted regulatory agencies to reevaluate the approval process of anti-diabetic therapies. As a result, in 2008, the Food and Drug Administration (FDA), and in 2012, the European Medicines Agency (EMA), issued requirements for the evaluation of cardiovascular safety outcomes of glucose-lowering therapies [3,4]. This development set the stage for the unexpected results of several large, randomized, placebo-controlled trials of SGLT2i which demonstrated convincing evidence of improved cardiovascular outcomes, including reduction in major adverse cardiovascular events (MACE) and hospitalizations for heart failure (HHF).
Cell membranes are composed largely of phospholipids and are impermeable to
large, polar molecules such as glucose. Therefore, glucose transport across cell
membranes requires specific membrane transport proteins. There are two classes of
glucose transporters in humans: the facilitated uniporter, GLUT, and the active
symporter, SGLT . Glucose transport via SGLT occurs by active transport,
a process that involves glucose absorption against its concentration gradient
using the energy provided by the sodium gradient across the membrane, which is
maintained by the Na
SGLT-2 is a low affinity-high capacity transporter  located in the epithelium of segment 1 of the proximal convoluted tubule  and is responsible for approximately 90% of filtered glucose reabsorption . The remaining ~10% of the filtered load is reabsorbed by SGLT-1, a high-affinity-low capacity transporter  located in segment 2 of the proximal convoluted tubule and segment 3 of the proximal straight tubule . However, complete pharmacologic blockade of SGLT-2 leads to only 50–60% excretion of filtered glucose due to downstream upregulation of SGLT-1 .
Glucose transport from the glomerular filtrate through the epithelial cell and into the blood is illustrated in Fig. 1 . Once active transport via SGLT leads to glucose uptake across the apical membrane into the epithelial cell, glucose transport to the peritubular capillary occurs via the basolateral facilitated glucose transporters, GLUT1, which colocalizes with SGLT1, and GLUT2, which colocalizes with SGLT2 .
Glucose reabsorption in the kidney. The majority (
The first SGLT2i Cardiovascular Outcomes Trial (CVOT) was EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes)  in 2015, which enrolled 7020 patients with T2DM and established cardiovascular disease. Despite a primary goal of only showing the cardiovascular safety of empagliflozin, the trial unexpectedly demonstrated a 14% reduction in MACE (a composite of cardiovascular death, nonfatal MI, and stroke), a 38% reduction in cardiovascular mortality, a 32% reduction in all-cause mortality, and a 32% reduction in HHF . Given these remarkable results, the investigators conducted post-hoc assessments that showed empagliflozin reduced cardiovascular events regardless of a past clinical diagnosis of heart failure (HF) (not phenotyped with preserved or reduced ejection fraction) , baseline risk for HF , and baseline cardiovascular risk .
These results were followed by the CANVAS (Canagliflozin Cardiovascular Assessment Study) program  in 2017, which enrolled 10,142 patients with T2DM and established, or risk factors for, cardiovascular disease. Similar to EMPA-REG OUTCOME, CANVAS showed a 14% reduction in MACE . Approximately 14% of enrolled patients had a history of either heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF) with similar benefits seen in both groups . Furthermore, reduction in cardiovascular death or HHF was greater among those with a history of HF .
Published in 2019, DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events – Thrombolysis in Myocardial Infarction 58) enrolled 17,160 patients with T2DM and established, or risk factors for, cardiovascular disease but did not demonstrate a reduction in MACE , which may be related to the large fraction of patients in the trial without cardiovascular disease . However, a post hoc analysis assessed patients by baseline HF status and found that dapagliflozin reduced HHF in patients irrespective of a history of HFrEF and reduced cardiovascular mortality and all-cause mortality in patients with HFrEF .
A meta-analysis of the original 3 CVOT’s showed that SGLT2i reduced the risk of cardiovascular death or HHF by 23% and that this reduction was independent of a documented history of HF (Table 1, Ref. [19-26,28]) . The same study also showed that there was greater reduction in HHF in patients with worse kidney function . Given the promising data on HF outcomes in all of the CVOT’s, it became clear that dedicated SGLT2i studies involving HF populations would be needed.
|EMPA-REG OUTCOME ||CANVAS ||DECLARE-TIMI 58 |
|Drug||Empagliflozin 10 mg or 25 mg vs placebo||Canagliflozin 100 mg or 300 mg vs placebo||Dapagliflozin 10 mg vs placebo|
|History of heart failure (reduced or preserved EF)||706 (10.1%)||1461 (14.4%)||1724 (10.0%)|
|Primary outcome||3 Point MACE (HR 0.86, 95% CI 0.74–0.99)||3 Point MACE (HR 0.86, 95% CI 0.75–0.97)||3 Point MACE (HR 0.93, 95% CI 0.84–1.03)|
|HHF outcome||HR 0.65, 95% CI 0.5–0.85||HR 0.67, 95% CI 0.52–0.87||HR 0.73, 95% CI 0.61–0.88|
|CV mortality||HR 0.62, 95% CI 0.49–0.77||HR 0.87, 95% CI 0.72–1.06||HR 0.98, 95% CI 0.82–1.17|
|Post-hoc analyses||CV events reduced regardless of|
|T2DM, type 2 diabetes mellitus 2; CV, cardiovascular; eGFR, estimated glomerular filtration rate; 3 Point MACE, three-point major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke); HR, hazard ratio; HHF, hospitalization for heart failure; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction.|
The first major SGLT2i trial specifically designed to assess HFrEF was DAPA-HF
(Dapagliflozin and the Prevention of Adverse-outcomes in Heart Failure), which
enrolled 4744 patients with NYHA II–IV symptoms and EF
|DAPA-HF ||EMPEROR-REDUCED ||SOLOIST-WHF ||EMPEROR-PRESERVED |
|Drug||Dapagliflozin 10 mg vs placebo||Empagliflozin 10 mg vs placebo||Sotagliflozin 400 mg vs placebo||Empagliflozin 10 mg vs placebo|
|Primary outcome||Hospitalization for HF or cardiovascular death, including urgent hospital visit with intravenous therapy for HF (HR 0.74, 95% CI 0.65–0.85)||Hospitalization for HF or cardiovascular death (HR 0.75, 95% CI 0.65–0.86)||Hospitalization of HF, urgent visit for HF, or cardiovascular death (HR 0.67, 95% CI 0.52–0.85)||Hospitalization for HF or cardiovascular death (HR 0.79, 95% CI 0.69–0.90)|
|HHF outcome||HR 0.70, 95% CI 0.59–0.83||HR 0.69, 95% CI 0.59–0.81||Not assessed individually||HR 0.71, 95% CI 0.60–0.83|
|CV mortality||HR 0.82, 95% CI 0.69–0.98||HR 0.92, 95% CI 0.75–1.12||HR 0.84, 95% CI 0.58–1.22||HR 0.91, 95% CI 0.76–1.09|
|HFrEF, heart failure with reduced ejection fraction; NYHA, New York Heart Association Class; T2DM, type 2 diabetes mellitus; eGFR, estimated glomerular filtration rate; PO, per os; HR, hazard ratio; CI, confidence interval; HHF, hospitalization for heart failure; KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score; SCORED, Sotagliflozin in patients with diabetes and chronic kidney disease; HFpEF, heart failure with preserved ejection fraction.|
DAPA-HF was followed by EMPEROR-REDUCED (Empagliflozin Outcome Trial in Patients
with Chronic Heart Failure and Reduced Ejection Fraction), which enrolled 3730
patients with NYHA II–IV symptoms and EF
Published in January 2021, SOLOIST-WHF (Effect of Sotagliflozin on
Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart
Failure) examined the efficacy of sotagliflozin in patients with T2DM and HFrEF
or HFpEF who had been stabilized from recent HF admission . Although it was
terminated early due to loss of funding in the setting of COVID-19, the trial
enrolled 1222 patients (79% with EF
|Trial||NCT identifier||Drug||Population||Enrollment||Primary endpoint|
|DETERMINE-REDUCED||03877237||dapagliflozin||HFrEF||313||6MWD and KCCQ|
|CHIEF-HF||04252287||canagliflozin||HFrEF and HFpEF||476||KCCQ|
|DELIVER||03619213||dapagliflozin||HFpEF||6263||Time to first CV death, HHF, or urgent HF visit|
|DAPA ACT HF-TIMI 68||04363697||dapagliflozin||HFrEF||2400||Time to first CV death or worsening HF|
|EMPULSE||04157751||empagliflozin||HFrEF and HFpEF||530||All-cause death, HF event, and KCCQ (Win Ratio)|
|MI and HF|
|EMPACT-MI||04509674||empagliflozin||STEMI/NSTEMI with new HF||3312||Time to first HHF or all-cause death|
|DAPA-MI||04564742||dapagliflozin||STEMI/NSTEMI with new HF||6400||Time to first HHF or CV death|
|HFrEF, heart failure with reduced ejection fraction; 6MWD, 6-minute walk distance; KCCQ, Kansas City Cardiomyopathy Questionnaire; HFpEF, heart failure with preserved ejection fraction; CV, cardiovascular; HHF, hospitalization for heart failure; MI, myocardial infarction; STEMI, ST elevation myocardial infarction; NSTEMI, non-ST elevation myocardial infarction.|
In the pooled analysis of SOLOIST-WHF and SCORED, sotagliflozin became the first agent to distinctly show benefit in HFpEF. However, SOLOIST-WHF was not designed to assess HFpEF as the primary hypothesis and HFpEF patients comprised only ~21% of the population . As such, a dedicated trial examining SGLT2i in HFpEF was needed.
Published in August 2021, EMPEROR-PRESERVED (Empagliflozin Outcome Trial in
Patients with Chronic Heart Failure with Preserved Ejection Fraction) 
enrolled 5988 patients with EF
EMPEROR-POOLED , a prospective, pooled analysis of EMPEROR-REDUCED and
EMPEROR-PRESERVED assessed the effect of empagliflozin on major renal events in
HF, defined as profound and sustained decreases in eGFR or renal replacement
therapy. The pooled study demonstrated a reduction in major renal events (2.8%
vs 3.5% for empagliflozin vs placebo). However, significant heterogeneity was
found between the two trials (p = 0.016 for interaction). Specifically,
the hazard ratios for major renal events were 0.51 (95% CI 0.33–0.79) in
EMPEROR-REDUCED compared to 0.95 (95% CI 0.73–1.24) in EMPEROR-PRESERVED,
indicating that renal benefit is primarily in HFrEF patients. As the
pathophysiology of HFrEF and HFpEF are profoundly different, it should not come
as a complete surprise that the cardiorenal interplay between the two HF
phenotypes differ as well. Finally, the fact that EMPEROR-PRESERVED demonstrated
a significant reduction in mean eGFR slope/year (–1.25 vs –2.62, p
The results from EMPEROR-PRESERVED are important given the paucity of options in HFpEF. The next major trial for SGLT2i and HFPEF is DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction)  which is scheduled to complete January 2022.
Without a prospective head-to-head comparison, it is challenging to extrapolate similarities and differences between individual SGLT2i to determine superiority. Available data demonstrate variation in “hard” outcomes such as MACE and cardiovascular death as well as relative efficacy in subgroups relating to subgroups of disease state and severity. Differences in patient populations, study protocols, or pharmacology of the drugs may account for these variations. However, the most consistent benefit across multiple populations and subgroups is the reduction in HHF. A meta-analysis of six outcomes trials studying four SGLT2i showed heterogeneity among the class with respect to cardiovascular death with the greatest and most consistent benefit seen in reduction of HHF .
DAPA-HF is the only trial thus far to demonstrate a mortality benefit in a dedicated HFrEF population. Various reasons for lack of a mortality benefit in EMPEROR-REDUCED have been proposed. One explanation highlights that, although both trials were underpowered for cardiovascular death, EMPEROR-REDUCED had significantly less power compared to DAPA-HF for mortality (500 cardiovascular deaths in DAPA-HF compared to 389 cardiovascular deaths in EMPEROR-REDUCED) . The investigators of EMPEROR-REDUCED note the study enrolled patients with lower EF and higher NT-proBNP compared to DAPA-HF (27.7% vs 31.2% and 1887 vs 1428 pg/mL, respectively). As such, it may seem curious that a “sicker” population would experience less overall cardiovascular death. However, this discrepancy may be explained by the higher overall event rate of the primary endpoint for EMPEROR-REDUCED, driven primarily by HHF, which led to shorter follow-up (16 vs 18.2 months) and lower accrual of cardiovascular death . Furthermore, a meta-analysis of DAPA-HF and EMPEROR-REDUCED demonstrated a 14% reduction in cardiovascular death (HR 0.86, 0.76–0.98, p = 0.027) and perhaps equally as important, failed to show a significant heterogeneity of effect between the two agents (Fig. 2) .
Meta-Analysis of the DAPA-HF and Emperor Reduced Trials. Note the negative tests for heterogeneity of effect between dapagliflozin and empagliflozin (Reproduced with permission from Zannad et al. ).
SOLOIST-WHF expanded beyond the findings from DAPA-HF and EMPEROR-REDUCED, although the latter two studies required a reduced EF. SOLOIST-WHF was unique in establishing the safety and efficacy of SGLT2i initiation in acute HF patients that have been stabilized, either prior to discharge or shortly thereafter. The cardiovascular mortality outcome was not met, but this must be taken in context with premature termination of the study (due to loss of funding) with a truncated median follow-up of 9 months.
Although SOLOIST-WHF provided evidence that SGLT2i could reduce HHF in HFpEF patients, EMPEROR-PRESERVED was the first large, dedicated HFpEF-SGLT2i trial to show benefit. The heart failure community awaits the results of DELIVER for comparison.
Finally, the relative SGLT selectivity of these agents has not manifested in overt clinical differences in large, randomized controlled trials. Empagliflozin exhibits an SGLT2:SGLT1 selectivity ratio of 2700 compared to 1200 for dapagliflozin and 20 for sotaglifozin . However, the results of DAPA-HF, EMPEROR-REDUCED, and SOLOIST-WHF are ostensibly comparable.
The unexpected results demonstrating cardiovascular benefit of SGLT2i in CVOT’s and subsequent trials confirming positive results in HF populations have spurred a flurry of research into these agents’ cardiac mechanism of action. SGLT2i appear to exhibit pleotropic effects on multiple molecular and physiologic systems mediated independently of anti-hyperglycemic activity . The actions of these drugs must also be appreciated in the context of a lack of SGLT2 receptors in the myocardium. Here, we will provide an overview of several categories of proposed mechanisms (Fig. 3), divided into direct and indirect cardiomyocyte benefit.
Proposed Mechanisms of SGLT2i HF Benefit. Several mechanisms of SGLT2i benefit in heart failure have been postulated, including augmented diuresis, improved calcium handling, protection of the cardiorenal axis, and reduced inflammation from multiple pathways, including those emanating from epicardial fat. The mechanisms for early reduction in hospitalizations for heart failure (HHF) and increase in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) remain unclear but may be related to augmented diuresis and improved contractility. Imaging data have demonstrated positive long-term remodeling, which may be explained by off-target attenuation of inflammatory pathways and fibrosis.
A striking feature of SGLT2i has been their ability to consistently increase erythropoietin and erythrocytosis across clinical trials . Interestingly, an increased hematocrit has been the strongest statistical variable associated with reduction in HHF and cardiovascular mortality [54,55]. However, increasing red blood cell mass through erythropoietin-analogs has not shown benefit in chronic HF patients, even in the setting of low hematocrit . One theory suggests that increased hematocrit may be a biomarker of the underlying mechanisms that provide benefit in HF .
SGLT2i induce a state of nutrient-deprivation that leads to transcriptional activation of a series of genes involved in adapting to cellular starvation (Fig. 4, Ref. ) . Specifically, the enzymes that act as low energy sensors include sirtuin 1 (SIRT1) and adenosine monophosphate-activated protein kinase (AMPK) . SIRT1 reduces oxidative stress by improving antioxidant activity  and AMPK protects mitochondrial function (Fig. 5) . Furthermore, SIRT1 and AMPK signaling stimulates autophagy, a critical process that clears the cell of damaged organelles , which are major sources of reactive oxygen species and cellular dysfunction in cardiomyocytes (Fig. 5) .
SGLT2i may exert cardioprotective effects by inducing a
nutrient- and oxygen-deprivation transcriptional paradigm. Sirtuin 1 (SIRT1) and
adenosine monophosphate-activated protein kinase (AMPK) are low energy sensors
that activate downstream pathways related to reduced oxidative stress and
improved autophagy. Erythrocytosis is also induced, although it may not be
central to a cardioprotective benefit. Reproduced with permission from Packer
et al.  (HIF-1
SGLT2i and Inflammatory Cascade in Heart Failure. (A) Heart
failure is characterized by mitochondrial dysfunction, diminished autophagic
flux, and generation of reactive oxygen species, resulting in an inflammatory and
fibrotic cascade. (B) SGLT2i activates SIRT1, which has antioxidant activity, and
AMPK, which improved mitochondrial function. Both SIRT1 and AMPK promote
autophagy, which also reduces inflammation (IL-1
How then is SIRT1/AMPK signaling related to erythrocytosis? In addition to inducing a fasting-like state, SGLT2i also lead to a state of hypoxia mimicry . Specifically, SIRT1 (induced by SGLT2i) activates hypoxia-inducible factor-2a (HIF-2a) [64,65], a hypoxia sensor that is a principal regulator of erythropoietin synthesis [57,59]. Thus, the increase in hematocrit demonstrated in SGLT2i clinical trials may serve as the laboratory marker of a complex enzymatic cascade of reduced oxidative stress and improved mitochondrial function.
Some clinical trials involving SGLT2i, such as DAPA-HF, have demonstrated a reduction in mortality, with survival curves separating after several months. This may suggest the ability to promote favorable long-term remodeling, as seen with beta-blockers, renin-angiotensin-aldosterone system (RAAS) and neprilysin inhibitors, and MRA [66,67].
Indeed, several mouse models studying SGLT2i have shown reduction in cardiac
fibrosis via reduced expression of transforming growth factor-
These laboratory findings were supported with clinical data in EMPA-HEART
CardioLink -6 (Effect of Empagliflozin on Left Ventricular Mass in Patients with
Type 2 Diabetes Mellitus and Coronary Artery Disease) , which evaluated
empagliflozin’s effect on LV remodeling in patients with established T2DM and
coronary artery disease and a normal EF. At 6 months, empagliflozin demonstrated
a significant decrease LV mass index vs placebo as demonstrated by cardiac
magnetic resonance (–2.6 vs –0.01 g/m
An important off-target effect of SGLT2i may relate to their high affinity
binding of the sodium-hydrogen exchanger-1 (NHE-1), which is expressed in
cardiomyocytes [73,74]. HF leads to a maladaptive increase in NHE-1 expression,
leading to a calcium and sodium overloaded state implicated in the pathogenesis
of cardiomyopathy [75,76]. Inhibition of NHE-1 decreases cytosolic Na
Another molecular hallmark of HF is the upregulation of Ca
In a healthy adult heart, the myocardium relies primarily on the mitochondrial oxidation of free fatty acids and to a lesser degree on the oxidation of glucose . In contrast, the failing heart shifts towards ketone production as a preferred method of energy production [82,83]. This has been theorized as an adaptive shift due to enhanced metabolic efficiency and energy production when ketones are used as the primary cardiac fuel [84,85]. SGLT2i have been shown to trigger a fasting-like state with increased fatty acid oxidation and ketogenesis . Thus, it has been suggested that SGLT2i mediate their cardiac benefit by promoting more efficient bioenergetics [86,87]. In addition, in a non-diabetic ischemic HF pig model, empagliflozin reduced adverse cardiac remodeling and also induced a shift from glucose as a myocardial substrate to ketone bodies, fatty acids, and branched-chain amino acids , though it was not proven whether the substrate shift was the cause of benefit or a coincident biomarker. Finally, infusion of beta-hydroxybutyrate in chronic HF patients has been shown to improve cardiac output and EF .
Others have argued against the theory of improved bioenergetics as the mechanism of cardiac benefit. For example, the elevation of ketones induced by SGLT2i is modest, especially in non-diabetic patients  and yet the presence of DMII in HF has not modified the CV outcomes of these drugs. Others have noted that the failing heart already uses ketones as fuel, that SGLT2i have not consistently increased ketone body consumption in experimental setting, and that enhanced ATP production in the setting of SGLT2i can be independent of ketone metabolism . As such, further studies are needed to elucidate the importance of cardiac bioenergetics as a mediator of SGLT2i benefit.
In addition to the anti-inflammatory benefit of mitigating oxidative stress,
SGLT2i have demonstrated attenuation of a multitude of other inflammatory
pathways in mice and humans. These include reduction of the activation of the
NLRP3/ASC inflammasome [90,91], reduction in the deposition of cardiotoxic lipids
, and reduction of a host of inflammatory mediators and cytokines, including
Several SGLT2i have shown a reduction in epicardial adipose [96-99], a profoundly metabolically active tissue that secretes profibrotic and pro-inflammatory cytokines . Epicardial adipose shares a common blood supply with the myocardium and is not separated from the myocardium by fascia . As such, epicardial adipose can cause a direct negative paracrine effect on myocardium via pro-inflammatory mediators . In addition, SGLT2i have demonstrated reduction in non-epicardial visceral adipose and subcutaneous adipose . Furthermore, mouse models have shown that SGLT2i can reduce adipose-mediated inflammation by reducing the ratio of pro-inflammatory M-1 macrophages to anti-inflammatory M-2 macrophages [103,104].
A common hypothesis regarding the mechanism of SGLT2i in reducing HHF centers on an augmented diuretic effect secondary to glucosuria and natriuresis [105,106]. SGLT2i lead to a ~300 mL/day increase in urinary output after 24 hours  with the increased urinary effect attenuated at 12 weeks . Natriuresis has been attributed to the colocalization of SGLT2 and the sodium hydrogen exchanger-3 (NHE3) in the proximal tubule of the nephron with a resultant off-target inhibition of NHE3 . One study suggests that the diuretic effect of SGLT2i may be even more robust when combined with loop diuretics . Furthermore, the rise in hematocrit seen in SGLT2i trials has been the strongest variable associated with reduction in HHF and CV mortality [53,54] – a laboratory effect that could plausibly be explained by volume depletion. Given the rapid onset of the SGLT2i diuretic effect, the early separation of curves for HHF in DAPA-HF and EMPEROR-REDUCED may also be explained by augmented diuresis . The early improvement in KCCQ-CSS seen in EMPEROR-REDUCED  would also be temporally consistent with this physiology. Finally, an early separation of curves has now been replicated in EMPEROR-PRESERVED . HFpEF patients have not typically responded to heart failure agents without a diuretic effect, offering further support for volume control as a potential mechanism to reduce HHF. Post-hoc analyses of interactions with loop diuretics and MRA’s in this trial would be of interest.
Arguments against the importance of a diuretic effect also exist . Firstly, the transient nature of SGLT2i-induced diuresis would not be consistent with a sustained reduction in HHF seen in clinical trials . Secondly, although some small studies have shown a synergistic diuretic effect between SGLT2i and loop diuretics , such an effect has not been replicated in larger clinical trials [29,111]. Furthermore, a secondary analysis of DAPA-HF demonstrated no difference in the primary composite outcome between loop diuretic subgroups, ranging from no use of loop diuretics to escalating doses . Thirdly, in EMPA-RESPONSE-AHF , which examined empagliflozin in an acutely decompensated HFrEF population, empagliflozin failed to reduce an objective dyspnea score, which would not be consistent with a drug thought to provide efficacious decongestion. Finally, trials have failed to demonstrate an acute drop in NT-proBNP, which would be expected from a diuretic effect . Taken altogether, compelling evidence for and against the importance of a diuretic effect in SGLT2i suggests the topic deserves further study.
SGLT2i have demonstrated a striking effect on renal endpoints in clinical trials [22,113]. Potential mechanisms of renal benefit include reduction of intraglomerular hypertension, reduction of oxidative stress and inflammation, and modulation of the sympathetic nervous system (SNS) . There is a pivotal interplay between the heart and kidney with dysfunction of one organ leading to dysfunction of the other [115,116]. A significant proportion of patients with HFrEF have concomitant renal dysfunction . The importance of the cardiorenal axis in HFrEF may be emphasized by evidence that SGLT2i provide greater reductions in HHF for worsening degrees of renal function . However, the results of EMPEROR-POOLED  suggest that the interplay between heart and kidney may differ in HFpEF.
The aberrant behavior of the SNS and the mechanism of established pharmacotherapies in attenuating this response has led some to postulate that SGLT2i may act in a similar fashion. The lack of a rise in heart rate despite reductions in volume and blood pressure may suggest SNS inhibition . Noradrenaline has been shown to increase the expression of SGLT2 in human kidney cells, suggesting a cross-talk between the SNS and SGLT2 . Furthermore, use of dapagliflozin in a mouse model reduced the expression of tyrosine hydroxylase and noradrenaline in the kidney and heart, which are surrogates of the SNS . In addition, chemical denervation of the SNS in a hypertensive, nondiabetic mouse model resulted in reduced expression of renal SGLT2 and concomitant improvements in blood pressure . Finally, use of dapagliflozin in a mouse model reduced cardiac and renal tyrosine hydroxylase staining and noradrenaline content . An editorial of the same study noted that improvements in tissue levels of SNS activation may be a “bystander response” secondary to improved hemodynamic and metabolic parameters and not causally related to cardiorenal benefit .
Conflicting laboratory data regarding SNS activation and SGLT2i also exist. A rat model suggested that treatment with empagliflozin did not significantly alter sympathetic activity . In addition, a study in T2DM patients showed that SGLT2i led to increased activation of the RAAS system . As such, the equipoise regarding the relationship between SGLT2i and the SNS indicate this interaction warrants further study.
How should a clinician implement SGLT2i in a patient with HF? Here, we offer several considerations relating to initiation of this drug class, summarized in Table 4.
|When to initiate|
|HF, heart failure; eGFR, estimated glomerular filtration rate; HD, hemodialysis; FDA, Food and Drug Administration; PO, per os; NPO, nil per os.|
In DAPA-HF, EMPEROR-REDUCED, and EMPEROR-PRESERVED, SGLT2i demonstrated benefit regardless of diabetic status. DAPA-HF and EMPEROR-REDUCED studied initiation of SGLT2i in chronic, ambulatory, compensated HFrEF patients while EMPEROR-PRESERVED studied SGLT2i in chronic, ambulatory compensated HFpEF patients. However, SOLOIST-WHF demonstrated that it is safe to initiate an SGLT2i in recently hospitalized acute HFrEF and HFpEF patients after clinical stabilization, leading some to argue for the early initiation of SGLT2i prior to discharge or shortly thereafter . Furthermore, whereas SOLOIST-WHF assessed patients with acute HFrEF who had been clinically stabilized, EMPA-RESPONSE-AHF was a smaller trial that studied acute HFrEF patients still requiring intravenous loop diuretics. EMPA-RESPONSE-AHF showed that initiation of empagliflozin in this population was safe and improved a composite HF endpoint at 60 days. Taken together, the data suggest than an SGLT2i can be safely initiated in the clinic setting or the peri-hospitalization period.
There is less consensus and virtually no evidence regarding the order in which to initiate SGLT2i with respect to beta-blockers, angiotensin receptor neprilysin inhibitors (ARNI), and MRA in HFrEF. Certainly, the minimal effect on blood pressure (~3–5 mmHg reduction)  is less limiting compared to other HF agents. One review suggests that SGLT2i should be considered for earlier introduction relative to other agents owing to their ability to reduce HHF and protect against subsequent renal dysfunction, which could have beneficial effects on starting other agents such as mineralocorticoid antagonists . Perhaps the most important point is that SGLT2i provide significant cardiac benefits to HFrEF patients irrespective of baseline HF therapy. As such, SGLT2i should be considered one of the cornerstones of HFrEF therapy and their initiation should be a priority for the HFrEF patient. In addition, given the paucity of therapeutic options in HFpEF, the results of EMPEROR-PRESERVED offer support for use of empagliflozin in this population.
It is important to understand that use of an SGLT2i will result in an early
decline in estimated glomerular filtrate rate (eGFR) of approximately 3–6
Is there an eGFR threshold after which a clinician should not initiate an
SGLT2i? There is no robust data to demonstrate harm (or benefit) of initiation in
CKD V, but our practice is guided by the enrollment criteria of large clinical
trials. Dapagliflozin has been studied in patients with eGFR as low as 25
Several adverse events have been reported with SGLT2i. Increased genitourinary infections secondary to glucosuria have been a point of concern. Despite the theoretical risk, rates of urinary tract infections (UTI) have been similar been drug and placebo in several trials . In EMPEROR-REDUCED, UTI’s were similar in the empagliflozin and placebo arms (4.9% vs 4.5%, respectively). However, in EMPEROR-PRESERVED, uncomplicated UTI’s were more common with empagliflozin (9.9 vs 8.1%) .
Mycotic genital infections, especially in women, occurred at a 4 to 8 times higher rates in drug arm across CANVAS, EMPA-REG, DECLARE, and DAPA-HF . However, they were rarely serious. Moreover, in EMPEROR-REDUCED, there was notable increase in overall genital infections (1.7% vs 0.6%) but rates of serious genital infections were similar (0.3% in each arm). Similarly, in EMPEROR-PRESERVED, there was an increase in uncomplicated genital infections (2.2% vs 0.7%), but comparable rates of complicated genital infections. Initial concerns about an increase in the rate of Fournier’s gangrene with SGLT2i have not been replicated in more recent trials .
Volume depletion is another adverse event of interest with SGLT2i. In DAPA-HF, there was no significant difference in volume depletion in drug vs placebo arm (7.5% vs 6.8%, respectively; p = 0.4). EMPEROR-REDUCED also showed a similar amount of volume depletion in each arm. Furthermore, hypoglycemia is generally not an issue in this drug class, as glucosuria is attenuated in patients without hyperglycemia .
CANVAS demonstrated an increased risk of amputation, but this has not been reproduced in large trials of other SGLT2i. Finally, ketoacidosis, and specifically euglycemic ketoacidosis, has been reported as a potential adverse event. EMPEROR-REDUCED reported no cases in either arm while DAPA-HF reported 3 cases in the drug arm compared to 0 in the placebo arm. EMPEROR-PRESERVED reported a similar number of cases in both arms. Factors predisposing to ketoacidosis are related to decreased PO intake in the setting of illness or NPO order prior to major surgery. For this reason, the FDA advises holding SGLT2i 3 days prior to surgery, especially in cases in which resumption of regular PO intake is not expected to occur soon after the procedure .
In January 2021, the American College of Cardiology released the 2021 Update to
the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure
Treatment, which classifies SGLT2-i as a Class I Therapy . In patients with
HFrEF Stage C, the document recommends first initiating either an ACEi/ARB/ARNI
or a beta-blocker, in any order. After this, both an MRA and an SGLT2i can be
considered. Specifically, SGLT2i are recommended for patients with NYHA II–IV
symptoms and those meeting eGFR criteria, which are
In August 2021, the European Society of Cardiology released Guidelines for the
diagnosis and treatment of acute and chronic heart failure, which classified
dapagliflozin and empagliflozin as a Class I, Level of Evidence A therapy for
HFrEF patients (EF
SGLT2i have been a serendipitous addition to the heart failure armamentarium. Multiple large randomized controlled trials have demonstrated that this class of medications is safe and efficacious at reducing HHF and cardiovascular mortality in symptomatic HFrEF patients, regardless of glycemic status, and can be initiated in an acute or chronic heart failure setting. There also appears to be a role for the use of SGLT2i in reducing HHF in HFpEF patients. The cardioprotective mechanism of action, specifically in HFrEF, remains a topic of continued debate and research. Heart failure specialists and other cardiologists, as well as nephrologists, diabetologists, and primary care physicians should familiarize themselves with the use of these medications, including expected physiologic and laboratory changes and potential adverse events. The future is exciting for SGLT2i with several more trials underway.
TD—Writing – Original Draft; TG—Writing – Review & Editing.
The authors thank Bryan Moss for assistance in medical illustration.
This research received no external funding.
Dr. DeSa declares no conflicts of interest; Dr. Gong declares AstraZeneca Speaker’s Bureau.